Oncogenic cancer/testis antigens: prime candidates for immunotherapy.
about
Ectopic Expression of Testis Germ Cell Proteins in Cancer and Its Potential Role in Genomic InstabilityImmunotherapy in endometrial cancer - an evolving therapeutic paradigmHeat shock protein 70-2 (HSP70-2) a novel cancer testis antigen that promotes growth of ovarian cancer.Differences in somatic mutation landscape of hepatocellular carcinoma in Asian American and European American populations.Manipulation of Innate and Adaptive Immunity through Cancer Vaccines.Lack of ADAM2, CALR3 and SAGE1 Cancer/Testis Antigen Expression in Lung and Breast Cancer.OVA12 promotes tumor growth by regulating p53 expression in human cancer cells.AKAP4 mediated tumor malignancy in esophageal cancerEIF2S3Y suppresses the pluripotency state and promotes the proliferation of mouse embryonic stem cellsPersonalized Oncology Meets Immunology: The Path toward Precision Immunotherapy.LEM domain containing 1 promotes oral squamous cell carcinoma invasion and endothelial transmigration.Profiling cancer testis antigens in non-small-cell lung cancer.Human Leukocyte Antigen (HLA) Peptides Derived from Tumor Antigens Induced by Inhibition of DNA Methylation for Development of Drug-facilitated Immunotherapy.Fibrous sheath interacting protein 1 overexpression is associated with unfavorable prognosis in bladder cancer: a potential therapeutic target.The lymph node pre-metastatic niche.Prevalence of plasma autoantibody against cancer testis antigen NY-ESO-1 in HTLV-1 infected individuals with different clinical statusDeep exploration of the immune infiltrate and outcome prediction in testicular cancer by quantitative multiplexed immunohistochemistry and gene expression profiling.Current status of engineered T-cell therapy for synovial sarcoma.Selection of epitopes from self-antigens for eliciting Th2 or Th1 activity in the treatment of autoimmune disease or cancer.Opa interacting protein 5 acts as an oncogene in bladder cancer.Comment on 'Tumour antigen expression in hepatocellular carcinoma in a low-endemic western area'.The Heat-Stable Enterotoxin Receptor, Guanylyl Cyclase C, as a Pharmacological Target in Colorectal Cancer Immunotherapy: A Bench-to-Bedside Current Report.Suppression of MAGE-A10 alters the metastatic phenotype of tongue squamous cell carcinoma cellsHuman germ/stem cell-specific gene TEX19 influences cancer cell proliferation and cancer prognosis.The downregulation of putative anticancer target BORIS/CTCFL in an addicted myeloid cancer cell line modulates the expression of multiple protein coding and ncRNA genes.Genome-wide identification of cancer/testis genes and their association with prognosis in a pan-cancer analysis.Sp17 Protein Expression and Major Histocompatibility Class I and II Epitope Presentation in Diffuse Large B Cell Lymphoma Patients.Early gastric cancer frequently has high expression of KK-LC-1, a cancer-testis antigen.Strategies for Bispecific Single Chain Antibody in Cancer Immunotherapy.Cancer/testis antigen SPATA19 is frequently expressed in benign prostatic hyperplasia and prostate cancer.Towards personalized, tumour-specific, therapeutic vaccines for cancer.Expression analysis of cancer-testis genes in prostate cancer reveals candidates for immunotherapy.Cancer stem cells as targets for immunotherapy.Melanoma: a prototype of cancer-testis antigen-expressing malignancies.Exomechip Analyses Identify Genes Affecting Mortality after HLA-Matched Unrelated Donor Blood and Marrow Transplantation.Depletion of DNMT1 in differentiated human cells highlights key classes of sensitive genes and an interplay with polycomb repression.Melanoma antigen family A4 protein produced by transgenic silkworms induces antitumor immune responses.PLAC1-specific TCR-engineered T cells mediate antigen-specific antitumor effects in breast cancer.Knockdown of fibrous sheath interacting protein 1 expression reduces bladder urothelial carcinoma cell proliferation and induces apoptosis via inhibition of the PI3K/AKT pathway.Expression of TDRD9 in a subset of lung carcinomas by CpG island hypomethylation protects from DNA damage.
P2860
Q26747510-BD1CBA29-45FF-4D7E-9F45-0879EAF790ECQ27020910-CFD3D894-C4C1-40D3-BCA4-DB79A2FD9E0FQ33850034-75E5EB50-5277-46B9-A6F7-A4CB45483ACFQ34529055-D7F3E998-F2AC-4128-9C0A-CA305F4F4BC3Q34552791-45DE2B5D-5833-4E30-85F1-EFC3647D3247Q35739798-888BCB5D-F7FA-457B-B35C-B2924B654B21Q36376797-6B8BD008-00BF-4414-AAA9-EBFE367FCA7CQ36841180-172489DE-6208-49FB-BDCA-FF01EBC31A86Q36998244-C6578FD6-B93F-4076-A4C6-5A714577877FQ37059928-460D8229-4D14-4F9D-8C96-2BC162EE25B0Q37061372-4270E349-99BA-4683-BB82-5261DBA8C141Q37277266-E76B55A4-1623-4BBE-B0EB-9753240C1F79Q38390185-06F27A08-EE82-4E08-9F9C-98267DDCC947Q38598956-8D5339CE-CBFA-4A09-92AC-45B78CAC427AQ38613301-0773A4F2-C365-479E-992F-4ECE217C609EQ38675283-A0F9732E-DF78-4694-BB9B-ED0ECFB50745Q38784424-7615A330-3DB9-4D29-9CC1-3A9E1B073534Q38916522-E10C6CAC-F2C8-4792-BC61-3ADDE986233DQ39038768-815B5A09-34B6-43CF-A4F0-EBC961E3D204Q40116026-C7EEEB98-ED1A-49FE-97D6-5E9BEE3E58D5Q41512508-65B87641-0BF2-438B-B8C3-73D28B9B37C3Q41669233-7C81460C-5824-4B05-97E2-7F0E870ED11CQ41682198-C52870BB-F18A-4BAA-A707-4E217B41EC37Q42290390-88DE705C-759E-48A1-A0D2-2AE51E7BADA6Q42778353-D52FE0D1-FD66-4C2B-9BC6-297D11B2719CQ47129963-425877BD-6EBC-4523-9406-2351951FB756Q47141906-96FF95C4-4C16-4BFB-BAAE-CB39711F507BQ47157952-1AA84795-B427-45C1-AD19-2B4A7AE05B58Q47335259-1D844B06-1558-4661-A854-974DA63C4827Q47708668-C3392A49-581B-473A-86B3-A37019177E8DQ47789519-8AD773F7-BE4A-460E-89D7-F78146EC0F48Q47876991-DE52ADD7-5547-47F5-BB3C-F086AB8034C4Q48278683-AAEA8066-28BF-46C9-B6C9-945DC6C37FC3Q50070352-667D94A4-E435-452E-B7D3-5B02F1B799FBQ52611870-BCD113FB-8235-4F79-BA7F-A20DB6A698AAQ52621266-0F7BDB8E-00F2-4887-9D40-070B17A503A0Q52643627-26DB7D3B-AF2E-48E8-963B-B45DBCAFC49CQ52647698-DA5DC8C2-437D-4682-9E4A-BFBB6364BA0FQ52718423-A9D7BF26-4C62-45F6-8FAF-461DBBF5FA4DQ52728038-5FB9EBA0-7AF8-4FF0-9F20-1B025C9494CB
P2860
Oncogenic cancer/testis antigens: prime candidates for immunotherapy.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Oncogenic cancer/testis antigens: prime candidates for immunotherapy.
@en
type
label
Oncogenic cancer/testis antigens: prime candidates for immunotherapy.
@en
prefLabel
Oncogenic cancer/testis antigens: prime candidates for immunotherapy.
@en
P2093
P2860
P50
P921
P356
P1433
P1476
Oncogenic cancer/testis antigens: prime candidates for immunotherapy
@en
P2093
Henrik J Ditzel
Mads H Andersen
Morten F Gjerstorff
P2860
P304
15772-15787
P356
10.18632/ONCOTARGET.4694
P407
P5008
P577
2015-06-01T00:00:00Z